Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.

@article{Holloway1997SkeletalEO,
  title={Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.},
  author={Leah Holloway and Lenore Kohlmeier and Kyla Kent and Robert Marcus},
  journal={The Journal of clinical endocrinology and metabolism},
  year={1997},
  volume={82 4},
  pages={
          1111-7
        }
}
The objectives of this study were to determine whether cyclic administration of recombinant human GH, with or without the antiresorptive agent, salmon calcitonin (CT), provides clinically meaningful increases in bone mineral density (BMD) at the lumbar spine and proximal femur in postmenopausal osteopenic women. The design of the study was a randomized clinical trial consisting of 12 56-day treatment cycles. Each cycle was initiated by a 12-day period of hormone administration, followed by 44… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Osteoporosis: combination therapy for better or worse.

  • Journal of musculoskeletal & neuronal interactions
  • 2003
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Human Growth Hormone Therapy

VIEW 1 EXCERPT
CITES RESULTS